You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said its T-cell test complements serology testing and provides a more comprehensive view of the adaptive immune response to SARS-CoV-2 infection.
Oxford Immunotec's T-Spot Discovery SARC-CoV-2 test will be used to assess whether Valneva's vaccine candidate induces a T-cell response.
The deal will enable PerkinElmer to grow its infectious disease testing portfolio to include latent tuberculosis detection, it said.
Oxford Immunotec said recent trial data suggest that individuals with SARS-CoV-2 specific T cells but without detectible antibodies may be protected from infection.
If approved, the kit would enable automated sample preparation for the company's T-SPOT.TB test using blood samples stored up to 54 hours at room temperature.
The firm's revenues in Asia were up compared to a year ago, but the coronavirus pandemic drove down revenues in the US, Europe, and the rest of the world.
News items for the in vitro diagnostic industry for the week of Oct. 19, 2020.
Fujirebio Diagnostics got the nod for a chemiluminescent enzyme immunoassay to measure levels of CA 15-3 and manage patients diagnosed with breast cancer.